SG11201809695TA - Modulators of the integrated stress pathway - Google Patents
Modulators of the integrated stress pathwayInfo
- Publication number
- SG11201809695TA SG11201809695TA SG11201809695TA SG11201809695TA SG11201809695TA SG 11201809695T A SG11201809695T A SG 11201809695TA SG 11201809695T A SG11201809695T A SG 11201809695TA SG 11201809695T A SG11201809695T A SG 11201809695TA SG 11201809695T A SG11201809695T A SG 11201809695TA
- Authority
- SG
- Singapore
- Prior art keywords
- co7d
- avenue
- international
- libertyville
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/90—Ring systems containing bridged rings containing more than four rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111111111 0 1101010 11111 010 11111 0 11 01111111 0011111100111111110 1111 0111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/193034 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: C07D 213/73 (2006.01) C07D 261/08 (2006.01) C07D 317/64 (2006.01) C07D 261/20 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. SC, TR, C07D 231/56 (2006.01) C07C 235/00 (2006.01) C07D 401/04 (2006.01) C07D 271/113 (2006.01) (84) Designated States (unless otherwise indicated, for every CO7D 237/14 (2006.01) CO7D 213/30 (2006.01) CO7D 237/16 (2006.01) CO7D 213/64 (2006.01) CO7D 405/08 (2006.01) CO7D 213/66 (2006.01) CO7D 241/18 (2006.01) A61K 31/44 (2006.01) CO7D 471/04 (2006.01) A61P 35/00 (2006.01) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TZ, TJ, LV, (21) International Application Number: PCT/US2017/031360 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, KM, ML, MR, NE, SN, TD, TG). GW, (22) International Filing Date: 05 May 2017 (05.05.2017) Published: — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: _ 62/332,278 05 May 2016 (05.05.2016) US (71) Applicants: CALICO LIFE SCIENCES [US/US]; 1170 = Veterans Blvd, South San Francisco, CA 94080 (US). AB- — BVIE, INC. [US/US]; 1 North Waukegan Road, North = Chicago, IL 60064 (US). Inventors: SIDRAUSKI, Carmelo; 20434 Walnut Ave, Saratoga, CA 95070 (US). PLIUSHCHEV, Marina; 1834 — (72) Ridge Avenue, Unit 108, Evanston, IL 60201 (US). FROST, Jennifer, M.; 635 Yorktown Lane, Gurnee, IL 60031 (US). BLACK, Lawrence, A.; 993 Green Meadow = = Avenue, Vernon Hills, IL 60061 (US). XU, Xiangdong; — _ 993 Green Meadow Avenue, Vernon Hills, IL 60061 (US). = SWEIS, Ramzi, Farath; 1012 Plaister Avenue, Lake Bluff, IL 60044 (US). SHI, Lei; 1908 Trevino Terrace, Vernon = Hills, IL 60061 (US). ZHANG, Qinwei, I.; 1820 S Falcon = Drive, Libertyville, IL 60048 (US). TONG, Yunsong; 1408 Braxton Road, Libertyville, IL 60048 (US). HUTCHINS, Charles, W.; 31005 Prairie Ridge Road, Green Oaks, IL = = 60048 (US). CHUNG, Seungwon; 1512 Virginia Avenue, = Libertyville, IL 60048 (US). DART, Michael, J.; 844 Yale = — Lane, Highland Park, IL 60035 (US). = — (74) Agent: LARKIN, Angelyn et al.; Goodwin Procter LLP, = 100 Northern Avenue, Boston, MA 02210 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, — 1-1 71' 0 en HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, M KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 0\ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 1-1 IN 1-1 (54) 0 Title: MODULATORS OF THE INTEGRATED STRESS PATHWAY N (57) : Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) 0 and for treating related diseases; disorders and conditions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332278P | 2016-05-05 | 2016-05-05 | |
PCT/US2017/031360 WO2017193034A1 (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809695TA true SG11201809695TA (en) | 2018-11-29 |
Family
ID=58709639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809695TA SG11201809695TA (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Country Status (34)
Country | Link |
---|---|
US (2) | US20190144440A1 (en) |
EP (2) | EP3452448B1 (en) |
JP (3) | JP6997766B2 (en) |
KR (2) | KR20230042146A (en) |
CN (2) | CN115947681A (en) |
AR (1) | AR110599A1 (en) |
AU (2) | AU2017260367B2 (en) |
BR (1) | BR112018072663A2 (en) |
CA (1) | CA3023162A1 (en) |
CL (1) | CL2018003142A1 (en) |
CO (1) | CO2018012946A2 (en) |
CR (2) | CR20210372A (en) |
DK (1) | DK3452448T3 (en) |
DO (1) | DOP2018000242A (en) |
EC (1) | ECSP18089579A (en) |
ES (1) | ES2973442T3 (en) |
FI (1) | FI3452448T3 (en) |
HR (1) | HRP20240218T1 (en) |
IL (2) | IL262722B (en) |
LT (1) | LT3452448T (en) |
MA (1) | MA44861B1 (en) |
MD (1) | MD3452448T2 (en) |
MX (2) | MX2021007146A (en) |
PE (2) | PE20190348A1 (en) |
PH (1) | PH12018502329A1 (en) |
PT (1) | PT3452448T (en) |
RS (1) | RS65214B1 (en) |
RU (2) | RU2022106770A (en) |
SG (1) | SG11201809695TA (en) |
SI (1) | SI3452448T1 (en) |
TW (1) | TWI763668B (en) |
UA (1) | UA125513C2 (en) |
UY (1) | UY37228A (en) |
WO (1) | WO2017193034A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3634952A1 (en) * | 2017-06-07 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
JP2020525513A (en) * | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamidobicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1 as an ATF4 inhibitor for treating cancer and other diseases -Carboxamide derivatives and related compounds |
CR20200054A (en) * | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compounds, compositions and methods |
UY37958A (en) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
BR112020008834A2 (en) | 2017-11-02 | 2020-12-22 | Calico Life Sciences Llc | MODULATORS OF THE INTEGRATED STRESS ROUTE |
UY37956A (en) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
MX2020006115A (en) | 2017-12-13 | 2020-11-09 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway. |
US20210130308A1 (en) * | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
KR20210021519A (en) | 2018-06-05 | 2021-02-26 | 프락시스 바이오테크 엘엘씨 | Inhibitors of the integrated stress response pathway |
BR112021000332A2 (en) * | 2018-07-09 | 2021-04-06 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
TWI771621B (en) * | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | Prodrug modulators of the integrated stress pathway |
CR20210426A (en) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compounds, compositions and methods |
CA3130511A1 (en) * | 2019-02-25 | 2020-09-03 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
WO2020216766A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
CA3137212A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
US11318133B2 (en) | 2019-06-12 | 2022-05-03 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
CR20220316A (en) * | 2019-12-06 | 2022-10-07 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
US20230125481A1 (en) | 2020-01-28 | 2023-04-27 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
AU2021236284A1 (en) | 2020-03-11 | 2022-08-18 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
JP2023546225A (en) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Modulators of integrated stress response pathways |
WO2022084447A1 (en) | 2020-10-22 | 2022-04-28 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
CN117098753A (en) | 2020-10-22 | 2023-11-21 | 埃沃特克国际有限责任公司 | Modulators of integrated stress response pathways |
CN116685319A (en) * | 2020-12-10 | 2023-09-01 | 阿德格罗生物制药控股有限公司 | Methods for treating metastatic cancer of the skin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US162A (en) | 1837-04-17 | Island | ||
US5212A (en) | 1847-07-31 | Richard m | ||
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (en) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION |
JP2594486B2 (en) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | Topical ophthalmic composition |
US20070185079A1 (en) * | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
GB0400196D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
WO2006012395A2 (en) | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
US7994211B2 (en) * | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
GB0516314D0 (en) * | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Compound |
MX2010003249A (en) * | 2007-09-25 | 2010-11-09 | Takeda Pharmaceutical | Polo-like kinase inhibitors. |
WO2012020762A1 (en) | 2010-08-10 | 2012-02-16 | アステラス製薬株式会社 | Hetero ring compound |
TWI538905B (en) * | 2010-12-22 | 2016-06-21 | H 朗德貝克公司 | Bicyclo [3.2.1] octyl amide derivatives and uses of same |
JP6806562B2 (en) * | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Regulator of the eIF2α pathway |
WO2015038778A1 (en) * | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
-
2017
- 2017-05-04 TW TW106114859A patent/TWI763668B/en active
- 2017-05-05 BR BR112018072663-0A patent/BR112018072663A2/en not_active Application Discontinuation
- 2017-05-05 PE PE2018002316A patent/PE20190348A1/en unknown
- 2017-05-05 KR KR1020237009107A patent/KR20230042146A/en not_active Application Discontinuation
- 2017-05-05 LT LTEPPCT/US2017/031360T patent/LT3452448T/en unknown
- 2017-05-05 RU RU2022106770A patent/RU2022106770A/en unknown
- 2017-05-05 MX MX2021007146A patent/MX2021007146A/en unknown
- 2017-05-05 DK DK17723899.5T patent/DK3452448T3/en active
- 2017-05-05 US US16/098,675 patent/US20190144440A1/en not_active Abandoned
- 2017-05-05 EP EP17723899.5A patent/EP3452448B1/en active Active
- 2017-05-05 FI FIEP17723899.5T patent/FI3452448T3/en active
- 2017-05-05 WO PCT/US2017/031360 patent/WO2017193034A1/en active Application Filing
- 2017-05-05 HR HRP20240218TT patent/HRP20240218T1/en unknown
- 2017-05-05 PE PE2023001939A patent/PE20231935A1/en unknown
- 2017-05-05 EP EP23213609.3A patent/EP4356971A2/en active Pending
- 2017-05-05 ES ES17723899T patent/ES2973442T3/en active Active
- 2017-05-05 KR KR1020187035249A patent/KR102512049B1/en active IP Right Grant
- 2017-05-05 UY UY0001037228A patent/UY37228A/en unknown
- 2017-05-05 MA MA44861A patent/MA44861B1/en unknown
- 2017-05-05 RU RU2018142740A patent/RU2769327C2/en active
- 2017-05-05 CN CN202211242583.XA patent/CN115947681A/en active Pending
- 2017-05-05 PT PT177238995T patent/PT3452448T/en unknown
- 2017-05-05 RS RS20240199A patent/RS65214B1/en unknown
- 2017-05-05 AR ARP170101183A patent/AR110599A1/en unknown
- 2017-05-05 UA UAA201812001A patent/UA125513C2/en unknown
- 2017-05-05 JP JP2019510575A patent/JP6997766B2/en active Active
- 2017-05-05 CN CN201780042069.2A patent/CN109641844B/en active Active
- 2017-05-05 MX MX2018013495A patent/MX2018013495A/en unknown
- 2017-05-05 CR CR20210372A patent/CR20210372A/en unknown
- 2017-05-05 SI SI201731474T patent/SI3452448T1/en unknown
- 2017-05-05 CA CA3023162A patent/CA3023162A1/en active Pending
- 2017-05-05 AU AU2017260367A patent/AU2017260367B2/en active Active
- 2017-05-05 SG SG11201809695TA patent/SG11201809695TA/en unknown
- 2017-05-05 CR CR20180574A patent/CR20180574A/en unknown
- 2017-05-05 MD MDE20190301T patent/MD3452448T2/en unknown
-
2018
- 2018-11-01 IL IL262722A patent/IL262722B/en unknown
- 2018-11-02 DO DO2018000242A patent/DOP2018000242A/en unknown
- 2018-11-05 CL CL2018003142A patent/CL2018003142A1/en unknown
- 2018-11-05 PH PH12018502329A patent/PH12018502329A1/en unknown
- 2018-11-29 CO CONC2018/0012946A patent/CO2018012946A2/en unknown
- 2018-11-30 EC ECSENADI201889579A patent/ECSP18089579A/en unknown
-
2020
- 2020-11-24 US US17/103,003 patent/US20220363678A1/en not_active Abandoned
-
2021
- 2021-09-26 IL IL286693A patent/IL286693A/en unknown
- 2021-12-17 JP JP2021204755A patent/JP7389786B2/en active Active
-
2022
- 2022-02-11 AU AU2022200946A patent/AU2022200946A1/en active Pending
-
2023
- 2023-11-17 JP JP2023195552A patent/JP2024023324A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809695TA (en) | Modulators of the integrated stress pathway | |
SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
SG11201806727TA (en) | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
SG11201407674TA (en) | D-amino acid compounds for liver disease | |
SG11201811643TA (en) | Compounds and methods for modulating rna function | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201901873PA (en) | Tablet compositions | |
SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |